Search

SoHO

Substances of Human Origin (SoHO)

EHA has been involved in the evaluation and revision of EU legislation on human blood and blood components, from the start of process in 2016 to the presentation of the European Commission’s proposed Substances of Human…

Read more

Support opportunities

EHA Ranking for 2024 is now accessible via this link. EHA thrives on the support of the biomedical industry and the medical profession. The variety of opportunities available for industry range from educational activities to the EHA Congress.

Read more

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more

Policy & advocacy

At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.

Read more

Rolling out CAR T across Europe

Prof Christine Chomienne talking about CAR T implementation challenges during the 7th EAPM Presidency Conference in Brussels.

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Read more